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Purpose. To evaluate the best-corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone
implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and
nonvitrectomized eyes.Methods. This multicenter retrospective cohort study included 112 patients with CME secondary to retinal
diseases treated pro re nata (PRN) with a 0.7mg intravitreal dexamethasone implant for 12 months. The BCVA, CRT, adverse
events, safety data, and number of implants were recorded. Results. Vitrectomized and nonvitrectomized eyes received means of
three implants and one implant, respectively, over 12 months (𝑃 < 0.001). The mean BCVA of all patients improved from 0.13 at
baseline to 0.33 (𝑃 < 0.001) 12 months after one (𝑃 = 0.001), two (𝑃 = 0.041), and three (𝑃 < 0.001) implants but not four implants
(𝑃 = 0.068). The mean baseline CRT decreased significantly (𝑃 < 0.001) from 463 to 254 microns after 12 months with one
(𝑃 < 0.001), two (𝑃 = 0.002), and three (𝑃 = 0.001) implants but not with four implants (𝑃 = 0.114). The anatomic and functional
outcomes were not significantly different between vitrectomized and nonvitrectomized eyes. Increased IOP was the most common
adverse event (23.2%). Conclusions. Dexamethasone implant administered PRN improved VA and decreased CRT in CME, with
possible long-term clinically relevant benefits for treating CME from various etiologies. Vitrectomized eyes needed more implants
compared with nonvitrectomized eyes.
1. Introduction
Cystoid macular edema (CME) is an important cause of
visual loss. It is usually related to vascular, infectious, and
inflammatory conditions such as retinal vein occlusions
(RVO), diabetic macular edema (DME), uveitis, postop-
erative macular edema, age-related macular degeneration,
and radiation retinopathy [1]. Various factors and many
presumedmechanisms can be involved in the pathogenesis of
CME. These include mechanical traction, vascular endothe-
lial growth factor- (VEGF-) induced CME, and inflammation
[2]. In the past decade, novel therapeutic targets have shifted
the treatment options from laser photocoagulation toward
pharmacologic treatments. Of these, intravitreal anti-VEGF
agents have been the most favored by most retina specialists.
One of the main drawbacks of anti-VEGF therapy is its
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short duration of actionwhichmandatesmonthly intravitreal
injections in many patients [3].
Many inflammatory factors have been associated with
CME of different etiologies. Intraocular corticosteroid ther-
apies may decrease edema by inhibiting these factors and
decreasing vascular permeability [2, 4]. The US Food and
Drug Administration approved a dexamethasone intravitreal
implant (Ozurdex, Allergan, Inc., Irvine, CA) for treating
CME associated with noninfectious posterior uveitis, RVO,
and DME. The sustained-release formulation was designed
to release dexamethasone from the implant for up to 6
months, thus controlling the inflammation for a longer
time without the need for monthly injections [5]. However,
steroid-related adverse events exist such as cataract formation
and intraocular pressure (IOP) increases. Injection-related
adverse events include retinal detachment and endoph-
thalmitis. Pharmacokinetic studies have suggested that drug
half-lives are shortened in vitrectomized eyes due to a more
rapid drug clearance compared to nonvitrectomized eyes
[6]. Other investigators have reported good results of the
dexamethasone intravitreal implant in this set of eyes [7, 8].
The current study compared the functional and anatomic
outcomes, adverse events, and number of intravitreal injec-
tions of the dexamethasone intravitreal implant between
vitrectomized and nonvitrectomized eyes during a 12-month
follow-up period.
2. Methods
This study was a multicenter, retrospective, open-label,
exploratory chart review of data collected from patients
with CME treated with one or more 0.7mg dexamethasone
implants at eight Latin American retina practices. The local
institutional review board of Universidade Federal de Sa˜o
Paulo approved the study protocol, which adhered to the
tenets of the Declaration of Helsinki.
2.1. Patient Selection. The inclusion criteria included eyes
with a retinal disease associatedwithCME in the study eye(s),
the absence of infectious uveitis as a cause of the CME,
consent to the off-label use of the implant, implantation of
at least one dexamethasone intravitreal implant, a minimal
of 12-month follow-up after the first injection, and no other
intravitreal injection of any drug for at least 6 months before
the dexamethasone implant.
The exclusion criteria included patients with an incom-
plete chart information during the follow-up period; patient
inability to complete the 12-month follow-up for any reason;
a history of glaucoma or infectious uveitis/retinitis; and
a previous intravitreal therapy such as Iluvien (pSivida,
Watertown, MA), Retisert (pSivida), or Durasert (pSivida).
2.2.Medical Chart Information. Data were collected from the
patient charts formonthly follow-up visits after implantation.
The data included gender, age, ocular history, symptom
duration, previous surgeries, IOP, best-corrected visual acuity
(BCVA), baseline and 12-month fluorescein angiography
(FA) images, baseline and monthly OCT findings after
intraocular injection of the dexamethasone implant, and
the number of dexamethasone implants needed to achieve
complete CME regression during the 12-month period. Any
adverse reactions related to the treatment, that is, increased
IOP and lens opacity, and ocular procedures performed
after dexamethasone implantation, that is, vitrectomy and
glaucoma or cataract surgery, were recorded for statistical
analysis.
2.3. Safety Analysis. The safety analysis assessed the changes
in lens status, IOP, and injection-related adverse effects.Other
secondary treatment-related adverse effects of the implants,
such as cataract surgery due to lens opacification, need for
topical IOP-loweringmedications, and glaucoma surgery due
to uncontrolled high IOP were also recorded.
2.4. Retreatment Criteria and Efficacy Analysis. The PRN
regimen was used, and retreatment was considered when
therewas a clinically significant decrease of 10 letters in BCVA
compared with baseline, a clinically significant increase of
50 𝜇min central retinal thickness (CRT) comparedwith base-
line, or a failure of the dexamethasone implant to produce a
complete resolution of the CME after a total of two-month
follow-up.
The drug efficacy was measured by calculating the mean
change in theCRTbased on theOCTfindings and the Snellen
BCVAmeasurements from baseline to the last follow-up visit
compared to the number of dexamethasone implants needed
to achieve complete CME regression.
2.5. Data Analysis and Statistical Methods. Continuous vari-
ables were summarized using descriptive statistics, including
the sample size, mean, standard error, median, minimum,
and maximum values. Categorical variables were summa-
rized in frequency and percentage tables. The mean changes
in the BCVA and CRT analyses included patients with a
dexamethasone implant and 12-month follow-up; the 95%
confidence intervals and statistical significancewere analyzed
using a generalized estimating equation model with a corre-
lation structure. The nature and frequency of adverse events
were tabulated throughout the study and summarized using
descriptive statistics. Statistical analyses were evaluated suing
the Mann-Whitney and Kruskal-Wallis tests. 𝑃 < 0.05 was
considered statistically significant.
3. Results
A total of 112 eyes of 112 patients (62 men (55%), 50 women
(45%))with amean age of 64.5±12.2 years (range, 19–88)were
included. Retreatmentwas needed for patientswith persistent
or recurrent CME visualized on OCT images. Table 1 shows
the patient demographic data.
Retinal disease subgroups with a sufficient number of
study eyes formeaningful analysis of functional and anatomic
outcomes included DME (𝑛 = 43 eyes), BRVO (𝑛 = 17
eyes), CRVO (𝑛 = 14 eyes), and Irvine-Gass (𝑛 = 10 eyes).
The groups with other etiologies were too small for separate
analysis but were combined in the group that included all of
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Table 1: Patient demographic data and the number of implants (𝑛 =
112 patients).
Female :male 50 (45%)/62 (55%)
Phakic/pseudophakic 31 (28%)/81 (72%)
Choroidal detachment 1 (0.9%)
Initial leakage on angiography 108 (96%)
Vitrectomized eyes 40 (36%)
Number of intravitreous implants
1 69
2 22
3 16
4 4
5 1
the study eyes. Table 2 shows the different etiologies of the
CME.
The dexamethasone implant failed to achieve a complete
resolution of the CME after a total of two-month follow-
up in sixty patients (54%). Persistent leakage on fluorescein
angiography at 12-month follow-up was present in seventy
patients (63%).
3.1. Number of Implants. The mean number of treatments
over the 12-month period was 1.35 (range, 1–5) in the entire
study population. During the 12 months, 69 (61.6%) eyes
needed one implant, 22 (19.6%) eyes two implants, 16 (14.3%)
eyes three implants, four eyes (3.6%) four implants, and
one eye (0.9%) five implants. The mean dexamethasone
retreatment time was 6 months (range, 2–12 months). The
mean number of implants in vitrectomized eyes during 12
months was three (range, 1–5), whereas nonvitrectomized
eyes received one implant (range, 1–3), a difference that
reached statistical significance (𝑃 < 0.001) (Table 3).
3.2. Snellen BCVA Analysis. The mean baseline BCVA was
0.13 in the entire study population; it improved significantly
to 0.33 12 months after the first implant (𝑃 < 0.001).
A separate analysis comparing the baseline with the 12-
month follow-up BCVA related to the number of implants
showed significant improvement in patients who received
one (𝑃 = 0.001), two (𝑃 = 0.041), and three (𝑃 <
0.001) dexamethasone implants; however, injection of four
implants did not result in a statistically significant (𝑃 =
0.068) difference (Table 4). The mean baseline BCVA in the
nonvitrectomized eyes was 0.20 and in the vitrectomized eyes
was 0.10 (𝑃 = 0.282). The 12-month mean BCVA in the
nonvitrectomized eyes was 0.33 and in the vitrectomized eyes
was 0.45, and this difference was not statistically significant
(𝑃 = 0.418) (Table 3).
A subgroup analysis of the causes of CME showed
statistically significant differences frombaseline to 12months.
There were no differences among the diseases at baseline
(𝑃 = 0.215); however, a statistically significant difference was
noticed at the 12-month period (𝑃 = 0.007) (Table 5).
Table 2: Causes of macular edema.
DME 43 (38%)
BRVO 17 (15%)
CRVO 14 (13%)
Irvine-Gass 10 (8.9%)
Age-related macular degeneration 7 (6.3%)
Epiretinal membrane 8 (7.1%)
CME in retinitis pigmentosa 4 (3.6%)
CME after primary pars plana vitrectomy
for retinal detachment 4 (3.6%)
Uveitis 2 (1.8%)
CNV associated with central serous
choroidopathy 1 (0.9%)
Pigment epithelial detachment 1 (0.9%)
CNV refractory to anti-VEGF in angioid
streaks 1 (0.9%)
DME, diabetic macular edema; BRVO, branch retinal vein occlusion; CRVO,
central retinal vein occlusion; CME, cystoid macular edema; CNV, choroidal
neovascularization; VEGF, vascular endothelial growth factor.
3.3. CRT. Themean baseline CRTmeasured on OCT images
decreased significantly (𝑃 < 0.001) from 463 microns (range,
214–920 microns) to 254 microns (range, 154–977 microns)
after 12 months of follow-up. Comparison of the baseline
CRTwith the 12-month follow-upCRT regarding the number
of implants showed statistically significant improvements
associated with injection of one (𝑃 < 0.001), two (𝑃 =
0.002), and three (𝑃 = 0.001) dexamethasone implants but
not with four implants (𝑃 = 0.114) (Table 6). The mean
baseline CRT in the nonvitrectomized eyes was 420 microns
(range, 243–920 microns) and in the vitrectomized eyes was
532 microns (range, 214–840) (𝑃 = 0.199). The 12-month
mean CRT in the nonvitrectomized eyes was 265 microns
(range, 194–977 microns) and in the vitrectomized eyes was
232microns (range, 154–741microns), and this differencewas
not statistically significant (𝑃 = 0.3) (Table 3).
A subgroup analysis of the causes of ME showed statisti-
cally significant differences from baseline to 12 months, with
no difference among the diseases (Table 5).
3.4. Adverse Events. Twenty-seven treatment-related adverse
events were reported after the first injection. The most
commonly reported drug-induced adverse event was an
increased IOP, with a total of 26 (23.2%) events in the
total population. All patients with this complication were
treated successfully with a topical medication and no IOP-
lowering surgery was required. The development of cataracts
was another treatment-related adverse event that occurred in
one patient (0.9%). In the current study, no injection-related
adverse event such as endophthalmitis, retinal detachment,
or ocular hypotony occurred.
4. Discussion
Anti-VEGF therapies remain the first-line option for treat-
ing CME associated with retinal diseases. A significant
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Table 3: Baseline and 12-month BCVA and CRT related to the numbers of implants.
Nonvitrectomized eyes (𝑛 = 72) Vitrectomized eyes (𝑛 = 40) P value∗
Baseline Snellen BCVA 0.20 (0.0–1.0) 0.10 (0.01–0.40) 0.282
12-month Snellen BCVA 0.33 (0.01–1.0) 0.45 (0.01–0.80) 0.418
Number of implants 1.0 (1.0–3.0) 3.0 (1.0–5.0) <0.001
Baseline CRT (microns) 420 (243–920) 532 (214–840) 0.199
12-month CRT (microns) 265 (194–977) 232 (154–741) 0.300
∗By the Mann-Whitney test.
Data are expressed as the mean (minimum–maximum).
BCVA, best-corrected visual acuity; CRT, central retinal thickness.
Table 4: Baseline and 12-month BCVA related to the numbers of
implants and vitrectomy.
Baseline BCVA 12-month BCVA 𝑃 value
Number of implants
All eyes 0.13 (0.00–1.00) 0.33 (0.01–1.00) <0.001
1 0.20 (0.00–0.67) 0.33 (0.01–1.00) 0.001
2 0.20 (0.01–1.00) 0.50 (0.01–1.00) 0.041
3 0.10 (0.00–0.33) 0.33 (0.10–0.80) <0.001
4 0.08 (0.01–0.20) 0.50 (0.20–0.80) 0.068
Vitrectomized
No 0.20 (0.00–1.00) 0.33 (0.01–1.00) 0.001
Yes 0.11 (0.01–0.40) 0.45 (0.01–0.80) <0.001
BCVA, best-corrected visual acuity.
Wilcoxon test.
proportion of patients who either do not respond optimally to
anti-VEGF therapy or have recurrent disease require frequent
injections, which can become a substantial burden. The
current study reports the results of using 0.7mg dexametha-
sone intravitreal implants administered PRN at eight Latin
American retina practices. All patients had VA that failed
to improve and CME that failed to resolve resulting from
a variety of retinal diseases in response to the current anti-
VEGF and other therapies.
In the current study, injection of the dexamethasone
implant resulted in significant improvements in BCVA and
CRT, which is consistent with the results of large studies
(MEAD and GENEVA) [9, 10]. In another retrospective
German study in which 102 patients with RVO received
one dexamethasone implant, significant improvements in
BCVA and reductions in CRT were also observed [11].
Regarding other ocular indications, a small retrospective
study of 27 patients with noninfectious uveitis reported that
with repeated dexamethasone implant injections the retinal
thickness improved and the inflammation resolved, which
resulted in improved ocular function [12]. Functional and
anatomic improvements after intravitreous implants have
also been reported in several case series of patients with
persistent DME [13–15].
In a similar study, Lam and associates [16] reported that
the mean number of injections to treat CME from different
causes was 1.7 ± 0.2, which was similar to our mean number
of dexamethasone implants of 1.35 (range, 1–5).Those authors
also showed that study eyes with uveitis had a better outcome
with the dexamethasone implant compared to the eyes with
other causes of CME. In our current study, however, no
differences among the different diseases were identified.
Another large retrospective study included 289 patients with
RVO-related ME who received two or more intravitreous
dexamethasone implants.The patients received a mean of 3.2
(range, 2–9) implants alone or combined with other thera-
pies and the CRT and VA improved with each subsequent
injection [17]. In the current study, when analyzing groups
based on the numbers of injections, the gain in the BCVA
and decrease in the CRT were not significant for patients
who received four intravitreal dexamethasone implants. This
may have been related to the disease severity and/or poor
prognosis that required more aggressive treatment.
Clinicians frequently encounter patients with vitrec-
tomized eyes who need intraocular injections. Many clini-
cians have speculated that the clearance of intravitreal anti-
VEGF in vitrectomized eyes differs from that in nonvitrec-
tomized eyes.The current literature is controversial regarding
the impact of drug pharmacokinetics in vitrectomized eyes.
In a rabbit model, Ahn and colleagues reported that the over-
all intraocular pharmacokinetic properties of ranibizumab
(Lucentis, Genentech Inc., South San Francisco, CA) in
vitrectomized eyes were similar to those in nonvitrectomized
eyes [18]. In contrast, Christoforidis et al. [19] and Kakinoki
et al. [20] showed that intravitreal half-life of bevacizumab
(Avastin, Genentech Inc.) and ranibizumab decreased signif-
icantly after vitrectomy and lensectomy. Chin and associates
reported that the concentration of intravitreal triamcinolone
acetonide decreased more rapidly in the vitrectomized eye
than in the nonvitrectomized eye, and therefore, faster clear-
ance of intravitreal triamcinolone acetonide must be consid-
ered when planning intravitreal injections in vitrectomized
eyes [21]. Pelegr´ın et al. recently compared dexamethasone
intravitreal implants in vitrectomized and nonvitrectomized
patients with noninfectious uveitis and reported a simi-
lar long-term safety profile and good response regarding
decreased CRT and BCVA, with no significant differences
in the numbers of reinjections [22]. In the current study,
however, subgroup analysis showed that the mean numbers
of injections in vitrectomized eyes during 12 months were
significantly (𝑃 < 0.001) higher than in nonvitrectomized
eyes over the same timeline to achieve the same anatomic and
functional outcomes. This difference may have been due to
the different diseases evaluated in the current study.
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Table 5: Subgroup analyses of baseline and 12-month BCVA levels and CRT on OCT images by disease.
DME
(𝑛 = 43 eyes)
BRVO
(𝑛 = 17 eyes)
CRVO
(𝑛 = 14 eyes)
Irvine-Gass
(𝑛 = 10 eyes) 𝑃 value
∗
BCVA
Baseline Snellen VA 0.13 (0.01–0.67) 0.20 (0.00–1.00) 0.06 (0.01–0.50) 0.20 (0.13–0.67) 0.215
12-month Snellen VA 0.37 (0.01–1.00) 0.33 (0.03–0.80) 0.04 (0.01–0.67) 0.67 (0.67–1.00) 0.007
OCT
Baseline CRT (𝜇m) 444 (214–746) 421 (302–674) 693 (415–840) 686 (313–777) 0.058
12-month CRT (𝜇m) 264 (164–702) 289 (203–741) 367 (213–700) 220 (216–244) 0.15
∗Kruskal-Wallis for independent samples.
Data are expressed as the mean (minimum–maximum).
OCT, optical coherence tomography; BCVA, best-corrected visual acuity; DME, diabetic macular edema; BRVO, branch retinal vein occlusion; CRVO, central
retinal vein occlusion; CRT, central retinal thickness.
Table 6: Baseline and 12-monthCRT related to numbers of implants
and vitrectomy.
Baseline CRT 12-month CRT 𝑃 value
Number of implants
All eyes 463 (214–920) 254 (154–977) <0.001
1 418 (244–920) 279 (196–977) <0.001
2 469 (302–746) 270 (164–634) 0.002
3 487 (214–777) 232 (185–402) 0.001
4 733 (510–840) 242 (168–741) 0.144
Vitrectomized
No 421 (243–920) 265 (194–977) <0.001
Yes 532 (214–840) 232 (154–741) <0.001
CRT, central retinal thickness.
Wilcoxon test.
To the best of our knowledge, the current study was the
first to compare the number of injections for dexamethasone
implants in vitrectomized compared to nonvitrectomized
eyes among different intraocular diseases and showed that the
vitrectomized patients needed more injections based on the
re-retreatment criteria in this retrospective series. Because
the diseases and demographic datawere similar between both
groups (𝑃 > 0.05), we hypothesized that the half-life of a drug
in the vitreous cavity of vitrectomized eyes was shorter and
therefore the need for reinjections was higher.
Previous studies have also reported greater VA increases
in pseudophakic eyes than in phakic eyes [9, 16]. The authors
reported that these findings were secondary to cataract
formation in phakic populations. Phakic patients are more
prone to cataract development as an adverse effect of steroids
especially in patients with diabetes [16, 23]. In the current
study, repeated dexamethasone implant treatment could
have increased the incidence of cataract development [24].
However, only one (0.9%) patient with diabetes developed a
cataract during the 12-month period.
In addition to the one patient in whom a cataract devel-
oped, increased IOP developed in 26 (23.2%) patients, which
was manageable using topical IOP-lowering medications
without a glaucoma filtering surgery. The rate of ocular
hypertension reported in this study is in agreement with
the phase III trials of the dexamethasone implant in which,
by the end of the study, no more than 24% of eyes with
RVO and 23% of eyes with uveitis required IOP-lowering
medications after treatment with the intravitreous implant
[25, 26]. Seventy (63%) patients had FA leakage and 60
(54%) patients had persistence ME at the end of follow-
up; however, these results did not agree with the significant
VA improvement and decreased CRT possibly because some
patients had only angiographic edema but no actually retinal
thickening on OCT or partial resolution of the increased
retinal thickness.
The major limitations of the current study were its retro-
spective and open-label design. No standardized assessments
were defined before treatment across the centers, assessment
tools such as OCT instruments were not normalized, and
adverse events were limited to those reported in the medical
charts. In addition, the patient data collected depended on
the number of implants injected, frequency of treatment, and
the length of the follow-up period. Analyses were limited to
include data recorded from the patient charts; consequently,
some extra information was not assessed.
In conclusion, the 0.7mg dexamethasone implant
improves VA and reduces the CRT in patients with CME
secondary to various etiologies. Vitrectomized eyes appear to
need more injections compared with nonvitrectomized ones.
No important complications were observed in the current
series. Further studies are needed to clarify the efficacy
and safety of the dexamethasone implant in various patient
populations in clinical settings.
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